Establishment Labs (NASDAQ: ESTA - Get Free Report) and OraSure Technologies (NASDAQ: OSUR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations. Analyst Recommendations This is a summary of

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded range of Motiva SmoothSilk® Round and Motiva SmoothSilk Ergonomix® breast implants for use in the United States. The approval adds 28 new sizes to the Motiva U.S. portfolio, including implants as sm.

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of new clinical and scientific data supporting Breast Tissue Preservation and its Minimally Invasive Platform. Establishment Labs also announced the product line extensions of both Mia® and Preservé™ with new sizes and supporting tools. The announcements.

Shares of Establishment Labs Holdings Inc. (NASDAQ: ESTA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average

Establishment Labs is leveraging FDA approval and U.S. market entry to drive higher-margin growth through procedure-based offerings like Preservé. Q2 2026 results showed 31.7% revenue growth, gross margin expansion to 70.6%, and U.S. sales accounting for 89% of total growth. Preservé delivers over 2x revenue per procedure versus traditional augmentation, but long-term success hinges on repeat utilization and durable economics.

A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture P

Shares of Establishment Labs Holdings Inc. (NASDAQ: ESTA - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company.

Deutsche Bank AG purchased a new position in shares of Establishment Labs Holdings Inc. (NASDAQ: ESTA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 128,138 shares of the company's stock, valued at approximately $10,996,000. Deutsche Bank AG owned 0.44%

Establishment Labs Holdings Inc. (ESTA) Q2 2026 Earnings Call Transcript

Establishment Labs NASDAQ: ESTA reported second-quarter revenue growth of 31.7% year over year, driven by continued rapid expansion in the United States, rising adoption of its Minimally Invasive platform and improving operating leverage.